Acute Ischemic Stroke: Epidemiology Forecast to 2027
July 2018
50
About the Report
About the Report
Acute Ischemic Stroke: Epidemiology Forecast to 2027
Summary
A stroke occurs when blood to the brain is either blocked or interrupted by blood clots or ruptured blood vessels; this deprives the brain of oxygen and nutrients, ultimately leading to the death of brain cells. Acute ischemic stroke (AIS) occurs due to an obstructed blood vessel that supplies blood to the brain, and is the predominant type of stroke, accounting for approximately 65-90% of stroke cases across the US, Europe, and Asia. The major risk factors associated with the development of AIS include both modifiable and non-modifiable conditions, such as hypertension, smoking, diabetes mellitus, obesity, age, and family history of stroke.
GlobalData epidemiologists utilized comprehensive, country-specific data from national stoke registries and peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast of first-ever diagnosed incident cases of AIS, diagnosed prevalent cases of AIS, and mortality of AIS. Moreover, GlobalData epidemiologists provide detailed, clinically relevant segmentations for first-ever diagnosed incident cases of AIS. Finally, uniform methodology was used across the 8MM to ensure meaningful comparisons across markets. Additional segmentations on AIS and transient ischemic attacks can be found in the GlobalData AIS Epidemiology Forecast Model.
GlobalData epidemiologists forecast that the first-ever diagnosed incident cases of AIS in the 8MM will grow by an annual growth rate (AGR) of 4.43%, from 2,570,175 cases in 2017 to 3,708,465 cases in 2027. In the 8MM in 2017, urban China had the highest number of first-ever diagnosed incident cases with 1,735,727, while the UK had the lowest number of first-ever diagnosed incident cases with 50,803. Additionally, GlobalData epidemiologists forecast that the diagnosed prevalent cases of AIS in the 8MM will grow by an AGR of 2.76%, from 17,968,771 cases in 2017 to 22,931,332 cases in 2027. In the 8MM in 2017, the US had the highest number of diagnosed prevalent cases with 6,760,839, while Spain had the lowest number of diagnosed prevalent cases with 346,779.
Scope
- The Acute Ischemic Stroke (AIS) Epidemiology Forecast Report provides an overview of the risk factors and global trends of AIS in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
- This report also includes a 10-year epidemiological forecast for first-ever diagnosed incident cases of AIS, diagnosed prevalent cases of AIS, and mortality of AIS. First-ever diagnosed incident cases are further segmented by age (18 to 85 years and older), sex, recurrence, and Trial of Org 10172 in Acute Stroke Treatment (TOAST) subtype (large-artery atherosclerosis, cardioembolism, small-artery occlusion, other determined cause, undetermined cause [cryptogenic]), while diagnosed prevalent cases are further segmented by age (18 to 85 years and older) and sex.
- The Acute Ischemic Stroke epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy
The Acute Ischemic Stroke (AIS) Epidemiology Forecast report will allow you to-
- Develop business strategies by understanding the trends shaping and driving the global AIS market.
- Quantify patient populations in the global AIS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AIS therapeutics in each of the markets covered.
- Understand magnitude of AIS population by recurrence, subtype, and mortality.
Products
Table of Contents
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Acute Ischemic Stroke: Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.